IP Scholars Question the Legality and Wisdom of Joint AG Proposal to Seize Remdesivir Patents

The following post comes from Colin Kreutzer, a 2E at Scalia Law and a Research Assistant at CPIP. By Colin Kreutzer While the vaccines are starting to roll out in the fight against COVID-19, the precise timelines for when they will be widely available continue to be uncertain. But we do have treatments currently available … Continue reading “IP Scholars Question the Legality and Wisdom of Joint AG Proposal to Seize Remdesivir Patents”

IP Scholars File Comments with OSTP on Public Access to Scholarly Publications

A group of intellectual property scholars filed comments yesterday with the Office of Science and Technology Policy (OSTP), asking it to forgo its plans to make all federally-funded scholarly publications free and open to the public upon initial publication. The comments were submitted in response to a notice of Request for Information (RFI) that was … Continue reading “IP Scholars File Comments with OSTP on Public Access to Scholarly Publications”

New York Times Recycles Discredited Positions on Government Patent Rights over Pharmaceuticals

By Sean O’Connor The New York Times is at it again. A year after its Editorial Board promoted flawed research on government rights to patented drugs as part of a price control plan, the Board floated the idea again, together with misinformation about the Bayh-Dole Act. Advocates looking for a magic bullet to reduce drug … Continue reading “New York Times Recycles Discredited Positions on Government Patent Rights over Pharmaceuticals”